Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer.

Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K.

Clin Cancer Res. 2020 Jan 17. pii: clincanres.2321.2019. doi: 10.1158/1078-0432.CCR-19-2321. [Epub ahead of print]

PMID:
31953310
2.

Sulforaphane enhances apoptosis induced by Lactobacillus pentosus strain S-PT84 via the TNFα pathway in human colon cancer cells.

Yasuda S, Horinaka M, Sakai T.

Oncol Lett. 2019 Oct;18(4):4253-4261. doi: 10.3892/ol.2019.10739. Epub 2019 Aug 14.

3.

Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2.

Aono Y, Horinaka M, Iizumi Y, Watanabe M, Taniguchi T, Yasuda S, Sakai T.

Biochem Biophys Res Commun. 2018 Nov 10;505(4):1203-1210. doi: 10.1016/j.bbrc.2018.10.050. Epub 2018 Oct 14.

PMID:
30327144
4.

The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.

Ono H, Sowa Y, Horinaka M, Iizumi Y, Watanabe M, Morita M, Nishimoto E, Taguchi T, Sakai T.

Breast Cancer Res Treat. 2018 Aug;171(1):43-52. doi: 10.1007/s10549-018-4815-x. Epub 2018 May 11.

PMID:
29752686
5.

FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.

Takamura T, Horinaka M, Yasuda S, Toriyama S, Aono Y, Sowa Y, Miki T, Ukimura O, Sakai T.

Oncol Rep. 2018 Feb;39(2):627-632. doi: 10.3892/or.2017.6127. Epub 2017 Dec 1.

PMID:
29207153
6.

Sulforaphane suppresses cell growth and collagen expression of keloid fibroblasts.

Kawarazaki A, Horinaka M, Yasuda S, Numajiri T, Nishino K, Sakai T.

Wound Repair Regen. 2017 Apr;25(2):224-233. doi: 10.1111/wrr.12512. Epub 2017 Feb 20.

PMID:
28120534
7.

A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.

Toriyama S, Horinaka M, Yasuda S, Taniguchi T, Aono Y, Takamura T, Morioka Y, Miki T, Ukimura O, Sakai T.

Mol Cancer Ther. 2016 Sep;15(9):2066-75. doi: 10.1158/1535-7163.MCT-16-0010. Epub 2016 Jul 12.

8.

The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.

Fujiwara J, Sowa Y, Horinaka M, Koyama M, Wakada M, Miki T, Sakai T.

Int J Oncol. 2016 Feb;48(2):854. doi: 10.3892/ijo.2015.3265. Epub 2015 Nov 25.

9.

Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.

Tanaka R, Tomosugi M, Horinaka M, Sowa Y, Sakai T.

PLoS One. 2015 May 8;10(5):e0125779. doi: 10.1371/journal.pone.0125779. eCollection 2015.

10.

PDK1 is a potential therapeutic target against angiosarcoma cells.

Wada M, Horinaka M, Yasuda S, Masuzawa M, Sakai T, Katoh N.

J Dermatol Sci. 2015 Apr;78(1):44-50. doi: 10.1016/j.jdermsci.2015.01.015. Epub 2015 Feb 7.

PMID:
25726712
11.

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.

Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T.

PLoS One. 2014 Nov 25;9(11):e113217. doi: 10.1371/journal.pone.0113217. eCollection 2014.

12.

Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells.

Horinaka M, Yoshida T, Tomosugi M, Yasuda S, Sowa Y, Sakai T.

Sci Rep. 2014 Aug 8;4:6000. doi: 10.1038/srep06000.

13.

[Application of molecular-targeting cancer prevention to tumor immunity].

Horinaka M.

Nihon Eiseigaku Zasshi. 2014;69(1):8-14. Review. Japanese.

14.

Peroxisome proliferator-activated receptor γ ligand troglitazone and TRAIL synergistically induce apoptosis.

Koyama M, Sowa Y, Horinaka M, Goda AE, Fujiwara J, Sakai T.

Oncol Rep. 2014 Feb;31(2):947-54. doi: 10.3892/or.2013.2868. Epub 2013 Nov 25.

PMID:
24276615
15.

Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation.

Todo M, Horinaka M, Tomosugi M, Tanaka R, Ikawa H, Sowa Y, Ishikawa H, Fujiwara H, Otsuji E, Sakai T.

Oncol Rep. 2013 Nov;30(5):2379-84. doi: 10.3892/or.2013.2713. Epub 2013 Aug 30.

PMID:
24002210
16.

A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.

Yamada T, Horinaka M, Shinnoh M, Yoshioka T, Miki T, Sakai T.

Int J Oncol. 2013 Oct;43(4):1080-6. doi: 10.3892/ijo.2013.2042. Epub 2013 Jul 30.

PMID:
23900601
17.

Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8.

Shinnoh M, Horinaka M, Yasuda T, Yoshikawa S, Morita M, Yamada T, Miki T, Sakai T.

Int J Oncol. 2013 Mar;42(3):903-11. doi: 10.3892/ijo.2013.1790. Epub 2013 Jan 23.

PMID:
23354042
18.

Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules.

Taniguchi H, Horinaka M, Yoshida T, Yano K, Goda AE, Yasuda S, Wakada M, Sakai T.

Mol Cancer Ther. 2012 Oct;11(10):2294-300. doi: 10.1158/1535-7163.MCT-12-0031. Epub 2012 Jul 11.

19.

The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.

Fujiwara J, Sowa Y, Horinaka M, Koyama M, Wakada M, Miki T, Sakai T.

Int J Oncol. 2012 May;40(5):1483-91. doi: 10.3892/ijo.2012.1353. Epub 2012 Feb 2. Erratum in: Int J Oncol. 2016 Feb;48(2):854.

PMID:
22328338
20.

Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.

Horinaka M, Yoshida T, Nakata S, Shiraishi T, Tomosugi M, Yoshikawa S, Wakada M, Sakai T.

Cancer Sci. 2012 Feb;103(2):282-7. doi: 10.1111/j.1349-7006.2011.02150.x. Epub 2011 Dec 13.

21.

"Combination-oriented molecular-targeting prevention" of cancer: a model involving the combination of TRAIL and a DR5 inducer.

Yoshida T, Horinaka M, Sakai T.

Environ Health Prev Med. 2010 Jul;15(4):203-10. doi: 10.1007/s12199-009-0128-3. Epub 2010 Jan 6.

22.

Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.

Yano K, Horinaka M, Yoshida T, Yasuda T, Taniguchi H, Goda AE, Wakada M, Yoshikawa S, Nakamura T, Kawauchi A, Miki T, Sakai T.

Int J Oncol. 2011 Feb;38(2):365-74. doi: 10.3892/ijo.2010.874. Epub 2010 Dec 15.

PMID:
21165560
23.

Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.

Koyama M, Izutani Y, Goda AE, Matsui TA, Horinaka M, Tomosugi M, Fujiwara J, Nakamura Y, Wakada M, Yogosawa S, Sowa Y, Sakai T.

Clin Cancer Res. 2010 Apr 15;16(8):2320-32. doi: 10.1158/1078-0432.CCR-09-2301. Epub 2010 Apr 6.

24.

Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.

Uchiyama H, Sowa Y, Wakada M, Yogosawa M, Nakanishi R, Horinaka M, Shimazaki C, Taniwaki M, Sakai T.

Cancer Sci. 2010 Mar;101(3):728-34. doi: 10.1111/j.1349-7006.2009.01449.x. Epub 2009 Nov 27.

25.

Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells.

Horinaka M, Yoshida T, Kishi A, Akatani K, Yasuda T, Kouhara J, Wakada M, Sakai T.

FEBS Lett. 2010 Feb 5;584(3):577-82. doi: 10.1016/j.febslet.2009.12.004. Epub 2009 Dec 6.

26.

Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells.

Yoshida T, Horinaka M, Takara M, Tsuchihashi M, Mukai N, Wakada M, Sakai T.

Environ Health Prev Med. 2008 Sep;13(5):281-7. doi: 10.1007/s12199-008-0041-1. Epub 2008 Jul 31.

27.

Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.

Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, Wakada M, Mizutani Y, Miki T, Sakai T.

Mol Cancer Res. 2008 Dec;6(12):1852-60. doi: 10.1158/1541-7786.MCR-08-0012.

28.

Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.

Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, Wakada M, Kataoka K, Yoshikawa T, Sakai T.

Cancer Res. 2008 Nov 1;68(21):8918-27. doi: 10.1158/0008-5472.CAN-08-1120.

29.

Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis.

Yoshida T, Konishi M, Horinaka M, Yasuda T, Goda AE, Taniguchi H, Yano K, Wakada M, Sakai T.

Biochem Biophys Res Commun. 2008 Oct 10;375(1):129-33. doi: 10.1016/j.bbrc.2008.07.131. Epub 2008 Aug 3.

PMID:
18680719
30.

Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.

Goda AE, Yoshida T, Horinaka M, Yasuda T, Shiraishi T, Wakada M, Sakai T.

Oncogene. 2008 May 29;27(24):3435-45. doi: 10.1038/sj.onc.1211008. Epub 2008 Jan 14.

PMID:
18193086
31.

Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin.

Yoshida T, Shiraishi T, Horinaka M, Wakada M, Sakai T.

Oncol Rep. 2007 Nov;18(5):1239-42.

PMID:
17914579
32.

Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis.

Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, Wakada M, Mizutani Y, Miki T, Nishikawa A, Sakai T.

Cancer Sci. 2007 Sep;98(9):1417-23. Epub 2007 Jul 23.

33.

Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand.

Yoshida T, Maoka T, Das SK, Kanazawa K, Horinaka M, Wakada M, Satomi Y, Nishino H, Sakai T.

Mol Cancer Res. 2007 Jun;5(6):615-25.

34.
36.
37.

The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand.

Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Sakai T.

Mol Cancer Ther. 2006 Apr;5(4):945-51.

38.

Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.

Matsui TA, Sowa Y, Yoshida T, Murata H, Horinaka M, Wakada M, Nakanishi R, Sakabe T, Kubo T, Sakai T.

Carcinogenesis. 2006 Sep;27(9):1768-77. Epub 2006 Mar 29.

PMID:
16571651
39.

Quercetin induces gadd45 expression through a p53-independent pathway.

Yoshida T, Maeda A, Horinaka M, Shiraishi T, Nakata S, Wakada M, Yogosawa S, Sakai T.

Oncol Rep. 2005 Nov;14(5):1299-303.

PMID:
16211300
40.

Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.

Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.

Cancer Res. 2005 Jul 15;65(14):6364-70.

41.

Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells.

Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Matsui H, Sakai T.

Oncogene. 2005 Nov 3;24(48):7180-9.

PMID:
16007131
42.

Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.

Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.

Cancer Res. 2005 Jul 1;65(13):5662-7.

43.

The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells.

Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Sakai T.

Biochem Biophys Res Commun. 2005 Aug 5;333(3):833-8.

PMID:
15963948
44.

Differential response at the hGABP/E4TF1 site of retinoblastoma gene promoter in human testicular seminoma cells.

Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.

Oncol Rep. 2005 May;13(5):871-4.

PMID:
15809752
45.

Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line.

Oki T, Sowa Y, Hirose T, Takagaki N, Horinaka M, Nakanishi R, Yasuda C, Yoshida T, Kanazawa M, Satomi Y, Nishino H, Miki T, Sakai T.

FEBS Lett. 2004 Nov 5;577(1-2):55-9.

46.

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.

Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T.

Oncogene. 2004 Aug 19;23(37):6261-71.

PMID:
15208660
47.

[Follow-up study of hepatic hemangiomas].

Kobayashi T, Kawano M, Tomita Y, Tamano T, Saegusa S, Horinaka M, Monma T, Oguma M, Yanagisawa N, Ohe T, et al.

Nihon Shokakibyo Gakkai Zasshi. 1995 Jan;92(1):41-6. Japanese.

PMID:
7861625
48.

Functional effects of glucocorticoid exposure during fetal life.

Fujii T, Horinaka M, Hata M.

Prog Neuropsychopharmacol Biol Psychiatry. 1993 Mar;17(2):279-93.

PMID:
8430219

Supplemental Content

Loading ...
Support Center